Stock Rating Upgrade
The Value Trend Rating for Celldex Therapeutics Inc (NASDAQ: CLDX) improved in the last week from D to C reflecting improving fundamentals and high Appreciation Potential. Details supporting this higher rating are included in our next report.
Recent Price Action
Celldex Therapeutics Inc (NASDAQ: CLDX) stock rose modestly by 0.4% on 4/8/24. The stock closed at $39.74. However, trading volume in this advance was exceptionally low at 30% of normal. The stock has been exceptionally strong relative to the market over the last nine months but has declined -5.3% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, CLDX is expected to continue to be a modest Value Builder.
Celldex Therapeutics has a current Value Trend Rating of C (Low Neutral). This VT Rating improved in recent days from D previously. This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Celldex Therapeutics has a very low Appreciation Score of 5 but a very high Power Rating of 88, with the Low Neutral Value Trend Rating the result.
Be the first to comment